Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12000467 | 0.79 | CSNK2A1 (0.33) | CSNK2A1RORC | |
| SCHEMBL12034413 | 0.78 | ALDH1A1 (0.42) | — | |
| SCHEMBL2617326 | 0.73 | KMT2A (0.49) | — | |
| SCHEMBL12220698 | 0.73 | IRAK4 (0.43) | — | |
| SCHEMBL6112972 | 0.73 | TSHR (0.39) | CSNK2A1RORC | |
| SCHEMBL24460269 | 0.72 | SLC6A4 (0.49) | CSNK2A1RORC | |
| SCHEMBL4152456 | 0.72 | PDE4B (0.42) | CSNK2A1 | |
| SCHEMBL2851014 | 0.72 | ALOX15 (0.37) | CSNK2A1RORC | |
| SCHEMBL6113174 | 0.72 | XDH (0.38) | CSNK2A1RORC | |
| SCHEMBL26386327 | 0.72 | CSNK2A1 (0.56) | CSNK2A1RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101083-A1 | S1P1 AGONISTS COMPRISING A BICYCLIC N-CONTAINING RING | GLAXO GROUP LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
| US-20120094979-A1 | THIAZOLE OR THIADIZALOE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | GLAXO WELLCOME HOUSE (GB) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094979-A1 | THIAZOLE OR THIADIZALOE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | S1PR1, S1PR5, S1PR2 | CSNK2A1 2115/4885RORC 196/4885 |
| US-20120101083-A1 | S1P1 AGONISTS COMPRISING A BICYCLIC N-CONTAINING RING | S1PR1, S1PR2, S1PR3 | CSNK2A1 2499/4885RORC 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.